Anticholinergic Drugs Linked to Increased Cardiovascular Disease Risk | News Medical

The medications many of us rely on for common conditions – allergies, bladder control, even depression – may carry an increased risk of cardiovascular problems, according to a large new study published in BMC Medicine. Researchers at the Karolinska Institutet in Sweden followed over half a million adults for up to 14 years and found a significant link between regular use of drugs with anticholinergic effects and a higher incidence of heart disease.

Anticholinergic drugs work by blocking the action of acetylcholine, a neurotransmitter that plays a vital role in many bodily functions. While effective for treating a range of ailments – including overactive bladder, asthma, and certain types of anxiety – these medications have long been associated with cognitive decline in older adults. This new research suggests their impact may extend to the cardiovascular system as well.

What are Anticholinergic Drugs?

The term “anticholinergic” covers a broad class of medications. Common examples include certain antihistamines (used for allergies, insomnia, and motion sickness), tricyclic antidepressants, and drugs prescribed for urinary incontinence. It’s important to note that not all medications within these categories have strong anticholinergic effects; SSRIs, a newer class of antidepressants, generally have weaker effects. The study utilized the Anticholinergic Cognitive Burden (ACB) scale to quantify the cumulative exposure to these drugs, assigning scores based on their potential to block acetylcholine. The research highlights that it’s the cumulative use – the total “anticholinergic burden” over time – that appears to be most concerning.

How Does This Affect the Heart?

The study suggests that anticholinergic drugs may disrupt the delicate balance of the parasympathetic nervous system, which plays a crucial role in regulating heart rate and blood pressure. By interfering with this system, these medications could potentially contribute to the development of cardiovascular disease. Researchers found that participants with the highest exposure to anticholinergic drugs had a 71% higher risk of a cardiovascular event – such as heart failure, arrhythmia, or artery disease – compared to those who didn’t use these medications at all. This increased risk was particularly pronounced for heart failure and various types of irregular heartbeat.

Nanbo Zhu, a postdoctoral researcher involved in the study, explained, “Many of these drugs are used by older people and by people with multiple medical conditions. We wanted to investigate whether the total exposure had any significance for the risk of developing cardiovascular disease over time.”

Understanding the Study’s Findings

The Stockholm-based study included 508,273 residents aged 45 and older with no prior history of major cardiovascular disease (excluding hypertension). Researchers analyzed participants’ medication records over a 14-year period, tracking their exposure to anticholinergic drugs and monitoring the incidence of cardiovascular events. The findings revealed a clear dose-response relationship: the higher the cumulative exposure to anticholinergic drugs, the greater the risk of cardiovascular disease. Specifically, the hazard ratio (HR) increased with annual cumulative exposure: 1.16 for 1-89 DDDs, 1.31 for 90-364 DDDs, and 1.71 for ≥ 365 DDDs. Karolinska Institutet news reports these findings.

It’s crucial to understand that this study is observational, meaning it can demonstrate an association but cannot definitively prove causation. Other factors, such as underlying health conditions and lifestyle choices, could also contribute to the observed link. As Hong Xu, assistant professor at the Department of Neurobiology, Care Sciences and Society, points out, “Our results indicate that the cumulative drug burden can affect heart regulation… This does not mean that the drugs should always be avoided, but that exposure should be monitored carefully.”

What Does This Mean for Patients?

This research doesn’t mean individuals should immediately stop taking prescribed anticholinergic medications. Abruptly discontinuing medication can be harmful. Instead, it underscores the importance of open communication with your healthcare provider. If you are taking medications with anticholinergic effects, discuss the potential risks and benefits with your doctor, especially if you have existing cardiovascular risk factors. A thorough review of your medication list, considering the cumulative anticholinergic burden, may be warranted.

It’s also important to remember that the absolute risk increase is still relatively small. While the study showed a 71% higher risk in the highest exposure group, this represents an increase from a baseline risk. The overall risk of cardiovascular disease is influenced by a multitude of factors, including age, genetics, diet, exercise, and smoking. News Medical provides further context on the study’s findings.

The Role of Clinical Practice and Future Research

The study’s findings emphasize the require for greater awareness among healthcare professionals regarding the potential cardiovascular effects of anticholinergic drugs. Monitoring the total drug burden – considering all medications a patient is taking – could become a standard practice in clinical settings. What we have is particularly important for older adults and individuals with multiple medical conditions, who are more likely to be prescribed multiple medications with anticholinergic properties.

Further research is needed to confirm these findings and to explore the underlying mechanisms by which anticholinergic drugs may affect the cardiovascular system. Clinical trials could help determine whether reducing anticholinergic burden can improve cardiovascular outcomes. Research is needed to identify alternative medications with fewer anticholinergic effects for conditions currently treated with these drugs.

Looking ahead, the researchers suggest that ongoing surveillance of medication use and cardiovascular events will be crucial for refining our understanding of this complex relationship. The Stockholm CREAtinine Measurements project, which provided the data for this study, serves as a valuable model for similar initiatives in other regions. Regular reviews of prescribing guidelines and updates to clinical practice recommendations will be essential to ensure that patients receive the safest and most effective care.